Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.40 |
| ▸ | ULK1 | O75385 | 8/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.40 |
| ▸ | ULK2 | Q8IYT8 | 2/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23811546 | 0.78 | LRRK2 (0.42) | MALT1LRRK2ULK1IRAK4UTS2R | |
| SCHEMBL14803665 | 0.74 | GRM4 (0.42) | LRRK2ULK1IRAK4ULK2UTS2R | |
| SCHEMBL24126365 | 0.73 | LRRK2 (0.45) | LRRK2ULK1IRAK4 | |
| SCHEMBL24375255 | 0.71 | LRRK2 (0.39) | MALT1LRRK2ULK1IRAK4UTS2R | |
| SCHEMBL14803613 | 0.69 | LRRK2 (0.43) | LRRK2ULK1 | |
| SCHEMBL14803591 | 0.69 | KDM4E (0.47) | LRRK2 | |
| SCHEMBL24375650 | 0.69 | LRRK2 (0.37) | MALT1LRRK2IRAK4UTS2R | |
| SCHEMBL16662496 | 0.68 | LRRK2 (0.41) | MALT1LRRK2ULK1IRAK4UTS2R | |
| SCHEMBL14803709 | 0.68 | KDM4E (0.50) | LRRK2TLR7 | |
| SCHEMBL25144321 | 0.67 | OPRL1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127271-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127271-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | PTPN1, PTPN7, PTPN9 | MALT1 1238/4885LRRK2 850/4885ULK1 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.